金吾财讯 | 赛默飞世尔（TMO）披露2026年第三季度财报，整体业绩优于市场预期，核心驱动力来自实验室产品及生物制药服务板块的亮眼表现。
公司总部位于马萨诸塞州沃尔瑟姆，三季度营收 121亿美元，同比增约9%，超出市场一致预期1.9亿美元；其中实验室产品和生物制药服务业务营收69亿美元，同比增长约15%，分析师此前预期为66亿美元。但生命科学解决方案、专业诊断两大业务营收不及预期，分别录得27亿美元、11亿美元，同比增速约5%、同比下滑约7%，市场预期分别为28亿美元、12亿美元。盈利端，赛默飞世尔调整后每股收益6.68美元，较预期高出0.28美元；调整后营业利润约30亿美元、调整后营业利润率约25%，均高于分析师预估的29亿美元、24%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.